Plasminogen-mediated matrix invasion and degradation by macrophages is dependent on surface expression of annexin II

Blood

Volumn 97, Issue 3, 2001, Pages 777-784

  Falcone, Domenick J ^a   Borth, Wolfgang ^b   Khan, K M Faisal ^b   Hajjar, Katherine A ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LIPOCORTIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL CELL; ARTICLE; CELL LYSATE; CHEMOTAXIS; ENZYME SPECIFICITY; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; HEALING; INFLAMMATORY CELL; LIGAND BINDING; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECEPTOR BINDING; TISSUE INJURY;

EID: 0035253824     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.3.777     Document Type: Article

References (72)

1. Endothelial-dependent mechanisms in chronic inflammatory leukocyte recruitment
2. Of man and meuse: Leukecyte and endothelial adhesion melecule deficiencies
3. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes
4. The urokinase receptor is required for human monocle chemotaxis in vitro
5. Plasminogen activation in healing human wounds
6. Inflammation in atheroma: Implications for plaque rupture and platelet-collagen interaction
7. Degradation of connective tissue matrices by macrophages; III, morphological and biochemical studies on extracellar, pericellular, and intracellular events in matrix proteolysis by macrophages in culture
8. Acetyl-LDL stimulates macrophage-dependent plasminogen activation and degradation of extracellular matrix
9. Macrophage and foam cell release of matrix bound growth factors: Role of plasminogen activation
10. Transforming growth factor-β1 stimulates macrophage urokinase expression release of matrix-bound growth factors role of plasminogen activation
11. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice
12. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis
13. Impaired arterial neointima formation in mice with disruption of the plasminogen gene
14. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice
15. Urokinose-generated plasmin activates matrix metalloproteinases during aneurysm formation
16. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
17. Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophage
18. Characterization of a macrophage-derived plasminogen-activator inhibitor: Similarities with placental urokinase inhibi tor
19. Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells
20. Regulation of plasminogen activator inhibitor-1 levels in human monocytes
21. Macrophage colony-stimulating factor and granufocytemacrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes
22. The plasminogen system and cell surfaces: Evidence far blasminogen and urokinase receptors on the same cell type
23. Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes
24. Plasminogen activation by receptor-bound urokinase: A kinetic study with both cell-associated and isolated receptor
25. The binding of plasminogen fragments to cultured human umbilical vein endothelial cells
26. Plasminogen binding sites in normal human skin
27. Binding of plasminogen to cultured human endothelial cells
28. Interaction of tissue plasminogen activator with a human endothelial cell 45-kilodalton plasminogen receptor
29. Characterizations of the plasminogen receptors of normaJ and rheumatoid arthritis human synovial fibroblasts
30. An endothelial cell receptor for ptasminogen/tissue activator, I: Identity with annexin II
31. Role of cell-surface lysines in plasminogen binding to cells: Identification of alphaenolase as a candidate plasminogen receptor
32. The role of an enolase-related molecule in plasminogen binding to cells
33. Increased expression of alpha-enolase in c-jun transformed rat fibroblasts without increased activation of plasminogen
34. The role of annexin II tetramer in the activation of plasminogen
35. +2-dependent regulators of membrane function
36. Expression of annexins on the surfaces of non-metastatic and metastatic human and rodent tumor cells
37. Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C
38. Stress-relaxation of fibroblasts in collagen matrices triggers ectocytosis of plasma membrane vesicles containing actin, annexins II and Vl, and beta 1 integrin receptors
39. Functional macrophage cell lines transformed by Abelson leukemia virus
40. Establishment and characterization of a human acute leukemia cell line (THP-1)
41. 2
42. Human atherosclerosis, II: Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions
43. KP1: A new monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue sections
44. Efficient trace-labelling of proteins with iodine
45. Regulation of macrophage receptorbound plasmin by autoproteolysis
46. Nelsestuen GL
47. Endothelial cell mediated conversion of glu-plasminogen to lys-plasminogen: Further evidence for assembly of the fibrinolytic system On the endothelial cell surface
48. Binding of Lys-plasminogen to monocytes/macrophages
49. Functional characteristics of receptor-bound urokinase on human monocytes: Catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitars
50. Extracellular matrix remodeling by metalloproteinases and plasminogen activators
51. The plasma proteases, thrombin and plasmin, degrade the proteoglycan of rabbit aorta segments in vitro: An integrated ultrastructural and biochemical study
52. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator
53. Impaired wound healing in mice with a disrupted plasminogen gene
54. An endothelial cell receptor for plasminogen/tissue plasminogen activator, I: Identity with annexin II
55. Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for the attenuation of vasculopathy
56. 2 (calpactin I) act in concert to regulate the state of assembly of GFAP intermediate filaments in vitro
57. Interaction of the fibrinolytic receptor, annexin II, with the endothelial cell surface - Essential role of endonexin repeat
58. The subcellular distribution of early endosomes is affected by the annexin 112p11(2) complex
59. Annexin II is a major component of fusogenic endosomal vesicles
60. Calcium-induced translocation of annexins to subcellular organelles of human neutrophils
61. Molecular characterization of phagosomes
62. Stress-relaxation of fibroblasts in collagen matrices triggets ectocytosis of plasma membrane vesicles containing actin, annexins II and VI and beta 1 integrin receptors
63. Identification of a key domain in annexin and 14-3-3 proteins that stimulate calcium-dependent exocytosis in permeabilized adrenal chromaffin cells
64. Regulation at plasminogen receptor expression on human monocytes and monocytoid cell lines
65. The role of an enolase-related molecule in plasminogen binding to cells
66. Plasminogen-binding protein associated with the plasma membrane of cultured embryonic rat neocortical neurons
67. Plasminogen binds specifically to alpha-enolase on rat neuronal plasma membrane
68. Purification of the plasmin receptor from human carcinoma cells and comparison to alpha-enolase
69. Analysis of a 45-kDa protein that binds to the Heymann nephritis autoantigen G P330
70. Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the acceleration of cell-associated plasminogen by tissue-type plasminogen activator
71. Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18
72. Loss of cell viability dramatically elevates cell surface plasminogen binding and activation